ID   STK4_HUMAN              Reviewed;         487 AA.
AC   Q13043; B2RCR8; Q15802; Q4G156; Q5H982; Q6PD60; Q9BR32; Q9NTZ4;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Serine/threonine-protein kinase 4;
DE            EC=2.7.11.1;
DE   AltName: Full=Mammalian STE20-like protein kinase 1;
DE            Short=MST-1;
DE   AltName: Full=STE20-like kinase MST1;
DE   AltName: Full=Serine/threonine-protein kinase Krs-2;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 4 37kDa subunit;
DE              Short=MST1/N;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 4 18kDa subunit;
DE              Short=MST1/C;
GN   Name=STK4; Synonyms=KRS2, MST1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-312.
RX   PubMed=7665586; DOI=10.1074/jbc.270.37.21695;
RA   Creasy C.L., Chernoff J.;
RT   "Cloning and characterization of a human protein kinase with homology to
RT   Ste20.";
RL   J. Biol. Chem. 270:21695-21700(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8816758; DOI=10.1073/pnas.93.19.10099;
RA   Taylor L.K., Wang H.C., Erikson R.L.;
RT   "Newly identified stress-responsive protein kinases, Krs-1 and Krs-2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10099-10104(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone, Brain, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-7; 16-94; 118-144; 152-181; 232-259; 270-282;
RP   292-301; 333-342; 384-402; 405-413; 421-465 AND 470-481, ACETYLATION AT
RP   MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Mammary carcinoma;
RA   Bienvenut W.V., Matallanas D., Cooper W.N., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   FUNCTION, HOMODIMERIZATION, AND ACTIVITY REGULATION.
RX   PubMed=8702870; DOI=10.1074/jbc.271.35.21049;
RA   Creasy C.L., Ambrose D.M., Chernoff J.;
RT   "The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory
RT   domain.";
RL   J. Biol. Chem. 271:21049-21053(1996).
RN   [9]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-326 AND ASP-349.
RX   PubMed=11278283; DOI=10.1074/jbc.m005109200;
RA   Lee K.-K., Ohyama T., Yajima N., Tsubuki S., Yonehara S.;
RT   "MST, a physiological caspase substrate, highly sensitizes apoptosis both
RT   upstream and downstream of caspase activation.";
RL   J. Biol. Chem. 276:19276-19285(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11517310; DOI=10.1073/pnas.181161698;
RA   Ura S., Masuyama N., Graves J.D., Gotoh Y.;
RT   "Caspase cleavage of MST1 promotes nuclear translocation and chromatin
RT   condensation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10148-10153(2001).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H2B.
RX   PubMed=12757711; DOI=10.1016/s0092-8674(03)00355-6;
RA   Cheung W.L., Ajiro K., Samejima K., Kloc M., Cheung P., Mizzen C.A.,
RA   Beeser A., Etkin L.D., Chernoff J., Earnshaw W.C., Allis C.D.;
RT   "Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile
RT   twenty kinase.";
RL   Cell 113:507-517(2003).
RN   [12]
RP   FUNCTION, ACTIVITY REGULATION, HOMODIMERIZATION, PHOSPHORYLATION AT
RP   THR-183, MUTAGENESIS OF LYS-59; THR-175; THR-177; THR-183 AND LEU-444, AND
RP   INTERACTION WITH RASSF1 AND NORE1.
RX   PubMed=15109305; DOI=10.1042/bj20040025;
RA   Praskova M., Khoklatchev A., Ortiz-Vega S., Avruch J.;
RT   "Regulation of the MST1 kinase by autophosphorylation, by the growth
RT   inhibitory proteins, RASSF1 and NORE1, and by Ras.";
RL   Biochem. J. 381:453-462(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH RASSF1.
RX   PubMed=16510573; DOI=10.1158/0008-5472.can-05-2951;
RA   Oh H.J., Lee K.-K., Song S.J., Jin M.S., Song M.S., Lee J.H., Im C.R.,
RA   Lee J.-O., Yonehara S., Lim D.-S.;
RT   "Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis.";
RL   Cancer Res. 66:2562-2569(2006).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH FOXO3.
RX   PubMed=16751106; DOI=10.1016/j.cell.2006.03.046;
RA   Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B.E.,
RA   DiBacco S., de la Iglesia N., Gygi S.P., Blackwell T.K., Bonni A.;
RT   "A conserved MST-FOXO signaling pathway mediates oxidative-stress responses
RT   and extends life span.";
RL   Cell 125:987-1001(2006).
RN   [15]
RP   INTERACTION WITH SAV1, FUNCTION, AND MUTAGENESIS OF LYS-59.
RX   PubMed=16930133; DOI=10.1111/j.1742-4658.2006.05427.x;
RA   Callus B.A., Verhagen A.M., Vaux D.L.;
RT   "Association of mammalian sterile twenty kinases, Mst1 and Mst2, with
RT   hSalvador via C-terminal coiled-coil domains, leads to its stabilization
RT   and phosphorylation.";
RL   FEBS J. 273:4264-4276(2006).
RN   [16]
RP   FUNCTION, INTERACTION WITH PKB/AKT1, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=17932490; DOI=10.1038/sj.emboj.7601872;
RA   Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N.,
RA   Rubin M.A., Yelick P.C., Freeman M.R.;
RT   "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct
RT   inhibitors of Akt1.";
RL   EMBO J. 26:4523-4534(2007).
RN   [17]
RP   PHOSPHORYLATION AT THR-387, AND INTERACTION WITH PKB/AKT1.
RX   PubMed=17726016; DOI=10.1074/jbc.m704542200;
RA   Jang S.W., Yang S.J., Srinivasan S., Ye K.;
RT   "Akt phosphorylates MstI and prevents its proteolytic activation, blocking
RT   FOXO3 phosphorylation and nuclear translocation.";
RL   J. Biol. Chem. 282:30836-30844(2007).
RN   [18]
RP   FUNCTION.
RX   PubMed=18328708; DOI=10.1016/j.cub.2008.02.006;
RA   Praskova M., Xia F., Avruch J.;
RT   "MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell
RT   proliferation.";
RL   Curr. Biol. 18:311-321(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-265; SER-320 AND THR-340, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   REVIEW.
RX   PubMed=19484742; DOI=10.1002/biof.47;
RA   Hergovich A., Hemmings B.A.;
RT   "Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling.";
RL   BioFactors 35:338-345(2009).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH TNNI3.
RX   PubMed=18986304; DOI=10.1042/bj20081340;
RA   You B., Yan G., Zhang Z., Yan L., Li J., Ge Q., Jin J.P., Sun J.;
RT   "Phosphorylation of cardiac troponin I by mammalian sterile 20-like kinase
RT   1.";
RL   Biochem. J. 418:93-101(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT THR-3; SER-320; THR-340; THR-367; SER-410 AND SER-414, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   FUNCTION, INTERACTION WITH RASSF2, AND SUBCELLULAR LOCATION.
RX   PubMed=19525978; DOI=10.1038/onc.2009.152;
RA   Cooper W.N., Hesson L.B., Matallanas D., Dallol A., von Kriegsheim A.,
RA   Ward R., Kolch W., Latif F.;
RT   "RASSF2 associates with and stabilizes the proapoptotic kinase MST2.";
RL   Oncogene 28:2988-2998(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   CAUTION.
RX   PubMed=19940129; DOI=10.1074/jbc.m109.059675;
RA   Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D.,
RA   Cheng J.Q.;
RT   "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic
RT   signaling through phosphorylation of threonine 120.";
RL   J. Biol. Chem. 285:3815-3824(2010).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   FUNCTION.
RX   PubMed=21245099; DOI=10.1158/0008-5472.can-10-2203;
RA   Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J.,
RA   Truksa J., Dong L.F., Ralph S.J., Neuzil J.;
RT   "Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a
RT   FoxO1-dependent manner.";
RL   Cancer Res. 71:946-954(2011).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR.
RX   PubMed=21512132; DOI=10.1158/0008-5472.can-10-4532;
RA   Cinar B., Collak F.K., Lopez D., Akgul S., Mukhopadhyay N.K.,
RA   Kilicarslan M., Gioeli D.G., Freeman M.R.;
RT   "MST1 is a multifunctional caspase-independent inhibitor of androgenic
RT   signaling.";
RL   Cancer Res. 71:4303-4313(2011).
RN   [31]
RP   INTERACTION WITH RASSF1, AND ACTIVITY REGULATION.
RX   PubMed=21199877; DOI=10.1074/jbc.m110.178210;
RA   Guo C., Zhang X., Pfeifer G.P.;
RT   "The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian
RT   STE20-like kinases MST1 and MST2.";
RL   J. Biol. Chem. 286:6253-6261(2011).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SIRT1.
RX   PubMed=21212262; DOI=10.1074/jbc.m110.182543;
RA   Yuan F., Xie Q., Wu J., Bai Y., Mao B., Dong Y., Bi W., Ji G., Tao W.,
RA   Wang Y., Yuan Z.;
RT   "MST1 promotes apoptosis through regulating Sirt1-dependent p53
RT   deacetylation.";
RL   J. Biol. Chem. 286:6940-6945(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   INVOLVEMENT IN TIIAC.
RX   PubMed=22294732; DOI=10.1182/blood-2011-09-378158;
RA   Abdollahpour H., Appaswamy G., Kotlarz D., Diestelhorst J., Beier R.,
RA   Schaffer A.A., Gertz E.M., Schambach A., Kreipe H.H., Pfeifer D.,
RA   Engelhardt K.R., Rezaei N., Grimbacher B., Lohrmann S., Sherkat R.,
RA   Klein C.;
RT   "The phenotype of human STK4 deficiency.";
RL   Blood 119:3450-3457(2012).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-340; THR-387; SER-410 AND
RP   SER-414, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   INTERACTION WITH MARK3 AND DLG5.
RX   PubMed=28087714; DOI=10.1101/gad.284539.116;
RA   Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S.,
RA   Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.;
RT   "DLG5 connects cell polarity and Hippo signaling protein networks by
RT   linking PAR-1 with MST1/2.";
RL   Genes Dev. 30:2696-2709(2016).
RN   [40]
RP   CAUTION, AND RETRACTION NOTICE OF PUBMED:28087714.
RX   PubMed=27825096; DOI=10.1074/jbc.a109.059675;
RA   Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D.,
RA   Cheng J.Q.;
RL   J. Biol. Chem. 291:22858-22858(2016).
RN   [41]
RP   INTERACTION WITH SCRIB.
RX   PubMed=28169360; DOI=10.1038/srep42125;
RA   Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R.,
RA   Chen H., Zhou C., Zhang J., Yang J., Liu P.;
RT   "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo
RT   signaling pathway.";
RL   Sci. Rep. 7:42125-42125(2017).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-162; GLN-310; MET-312; THR-355 AND
RP   LEU-416.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated, pro-apoptotic kinase which, following
CC       caspase-cleavage, enters the nucleus and induces chromatin condensation
CC       followed by internucleosomal DNA fragmentation. Key component of the
CC       Hippo signaling pathway which plays a pivotal role in organ size
CC       control and tumor suppression by restricting proliferation and
CC       promoting apoptosis. The core of this pathway is composed of a kinase
CC       cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory
CC       protein SAV1, phosphorylates and activates LATS1/2 in complex with its
CC       regulatory protein MOB1, which in turn phosphorylates and inactivates
CC       YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2
CC       inhibits its translocation into the nucleus to regulate cellular genes
CC       important for cell proliferation, cell death, and cell migration.
CC       STK3/MST2 and STK4/MST1 are required to repress proliferation of mature
CC       hepatocytes, to prevent activation of facultative adult liver stem
CC       cells (oval cells), and to inhibit tumor formation (By similarity).
CC       Phosphorylates 'Ser-14' of histone H2B (H2BS14ph) during apoptosis.
CC       Phosphorylates FOXO3 upon oxidative stress, which results in its
CC       nuclear translocation and cell death initiation. Phosphorylates
CC       MOBKL1A, MOBKL1B and RASSF2. Phosphorylates TNNI3 (cardiac Tn-I) and
CC       alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac
CC       Tn-T). Phosphorylates FOXO1 on 'Ser-212' and regulates its activation
CC       and stimulates transcription of PMAIP1 in a FOXO1-dependent manner.
CC       Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53
CC       deacetylation, thereby promoting p53/TP53 dependent transcription and
CC       apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1.
CC       Phosphorylates AR on 'Ser-650' and suppresses its activity by
CC       intersecting with PKB/AKT1 signaling and antagonizing formation of AR-
CC       chromatin complexes. {ECO:0000250|UniProtKB:Q9JI11,
CC       ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:11517310,
CC       ECO:0000269|PubMed:12757711, ECO:0000269|PubMed:15109305,
CC       ECO:0000269|PubMed:16510573, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:17932490,
CC       ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18986304,
CC       ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:21212262,
CC       ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:21512132,
CC       ECO:0000269|PubMed:8702870, ECO:0000269|PubMed:8816758}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Inhibited by the C-terminal non-catalytic region.
CC       Activated by caspase-cleavage. Full activation also requires
CC       homodimerization and autophosphorylation of Thr-183. Activated by
CC       RASSF1 which acts by preventing its dephosphorylation.
CC       {ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:21199877,
CC       ECO:0000269|PubMed:8702870}.
CC   -!- SUBUNIT: Homodimer; mediated via the coiled-coil region. Interacts with
CC       NORE1, which inhibits autoactivation. Interacts with and stabilizes
CC       SAV1. Interacts with RASSF1. Interacts with FOXO3. Interacts with
CC       RASSF2 (via SARAH domain). Interacts with AR, PKB/AKT1, TNNI3 and
CC       SIRT1. Interacts with DLG5 (via PDZ domain 3). Interacts with MARK3 in
CC       the presence of DLG5 (PubMed:28087714). Interacts with SCRIB in the
CC       presence of DLG5 (PubMed:28169360). {ECO:0000250|UniProtKB:Q13188,
CC       ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:16510573,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:16930133,
CC       ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,
CC       ECO:0000269|PubMed:18986304, ECO:0000269|PubMed:19525978,
CC       ECO:0000269|PubMed:21199877, ECO:0000269|PubMed:21212262,
CC       ECO:0000269|PubMed:21512132, ECO:0000269|PubMed:28087714,
CC       ECO:0000269|PubMed:28169360}.
CC   -!- INTERACTION:
CC       Q13043; P31749: AKT1; NbExp=13; IntAct=EBI-367376, EBI-296087;
CC       Q13043; O95166: GABARAP; NbExp=2; IntAct=EBI-367376, EBI-712001;
CC       Q13043; Q9H0R8: GABARAPL1; NbExp=2; IntAct=EBI-367376, EBI-746969;
CC       Q13043; P60520: GABARAPL2; NbExp=2; IntAct=EBI-367376, EBI-720116;
CC       Q13043; Q9GZQ8: MAP1LC3B; NbExp=7; IntAct=EBI-367376, EBI-373144;
CC       Q13043; Q9H8S9: MOB1A; NbExp=9; IntAct=EBI-367376, EBI-748229;
CC       Q13043; Q7L9L4: MOB1B; NbExp=4; IntAct=EBI-367376, EBI-2558745;
CC       Q13043; Q06830: PRDX1; NbExp=11; IntAct=EBI-367376, EBI-353193;
CC       Q13043; Q9NS23-2: RASSF1; NbExp=4; IntAct=EBI-367376, EBI-438698;
CC       Q13043; P50749: RASSF2; NbExp=16; IntAct=EBI-367376, EBI-960081;
CC       Q13043; Q86WH2: RASSF3; NbExp=6; IntAct=EBI-367376, EBI-2845202;
CC       Q13043; Q9H2L5: RASSF4; NbExp=6; IntAct=EBI-367376, EBI-2933362;
CC       Q13043; Q8WWW0: RASSF5; NbExp=8; IntAct=EBI-367376, EBI-367390;
CC       Q13043; Q8WWW0-2: RASSF5; NbExp=4; IntAct=EBI-367376, EBI-960502;
CC       Q13043; Q8WWW0-3: RASSF5; NbExp=2; IntAct=EBI-367376, EBI-960507;
CC       Q13043; Q6ZTQ3: RASSF6; NbExp=4; IntAct=EBI-367376, EBI-2933412;
CC       Q13043; Q9H4B6: SAV1; NbExp=19; IntAct=EBI-367376, EBI-1017775;
CC       Q13043; Q14BN4: SLMAP; NbExp=7; IntAct=EBI-367376, EBI-1043216;
CC       Q13043; Q13188: STK3; NbExp=19; IntAct=EBI-367376, EBI-992580;
CC       Q13043; Q13043: STK4; NbExp=4; IntAct=EBI-367376, EBI-367376;
CC       Q13043; P35700: Prdx1; Xeno; NbExp=3; IntAct=EBI-367376, EBI-444948;
CC       Q13043; Q91VJ4: Stk38; Xeno; NbExp=2; IntAct=EBI-367376, EBI-2527046;
CC       Q13043-1; Q8WWW0-1: RASSF5; NbExp=3; IntAct=EBI-15638366, EBI-960496;
CC       Q13043-1; Q9H4B6: SAV1; NbExp=2; IntAct=EBI-15638366, EBI-1017775;
CC       Q13043-1; Q13043-1: STK4; NbExp=4; IntAct=EBI-15638366, EBI-15638366;
CC       Q13043-2; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-14280485, EBI-742054;
CC       Q13043-2; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-14280485, EBI-79165;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=The caspase-cleaved form
CC       cycles between the nucleus and cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13043-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13043-2; Sequence=VSP_019851, VSP_019852;
CC   -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase
CC       from the normal to the malignant state (at protein level). Ubiquitously
CC       expressed. {ECO:0000269|PubMed:17932490}.
CC   -!- INDUCTION: Activity increases during mitosis.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       Phosphorylation at Thr-387 by PKB/AKT1, leads to inhibition of its:
CC       kinase activity, nuclear translocation and autophosphorylation at Thr-
CC       183. It also diminishes its cleavage by caspases and its ability to
CC       phosphorylate FOXO3. {ECO:0000269|PubMed:11278283,
CC       ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:17726016,
CC       ECO:0000269|PubMed:19940129}.
CC   -!- PTM: Proteolytically cleaved by caspase-3 during apoptosis at Asp-326
CC       and Asp-349 resulting in a 37 kDa or a 39 kDa subunit respectively. The
CC       39 kDa subunit is further cleaved into the 37 kDa form. Proteolytic
CC       cleavage results in kinase activation and nuclear translocation of the
CC       truncated form (MST1/N). It is less likely that cleavage at Asp-349 is
CC       a prerequisite for activation as this site is not conserved in the
CC       murine ortholog. {ECO:0000269|PubMed:11278283}.
CC   -!- DISEASE: T-cell immunodeficiency, recurrent infections, and
CC       autoimmunity with or without cardiac malformations (TIIAC)
CC       [MIM:614868]: A primary T-cell immunodeficiency syndrome characterized
CC       by progressive loss of naive T-cells, recurrent bacterial, viral, and
CC       fungal infections, warts, and abscesses, autoimmune manifestations, and
CC       cardiac malformations, including atrial septal defect.
CC       {ECO:0000269|PubMed:22294732}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be phosphorylated at Thr-120
CC       (PubMed:19940129). However, this work has been retracted
CC       (PubMed:27825096). {ECO:0000269|PubMed:19940129,
CC       ECO:0000305|PubMed:27825096}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH29511.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH58916.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STK4ID42440ch20q11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U18297; AAA83254.1; -; mRNA.
DR   EMBL; U60207; AAB17262.1; -; mRNA.
DR   EMBL; AK315238; BAG37665.1; -; mRNA.
DR   EMBL; Z93016; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL109839; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75882.1; -; Genomic_DNA.
DR   EMBL; BC029511; AAH29511.1; ALT_SEQ; mRNA.
DR   EMBL; BC058916; AAH58916.1; ALT_SEQ; mRNA.
DR   EMBL; BC093768; AAH93768.1; -; mRNA.
DR   CCDS; CCDS13341.1; -. [Q13043-1]
DR   CCDS; CCDS86957.1; -. [Q13043-2]
DR   RefSeq; NP_006273.1; NM_006282.3. [Q13043-1]
DR   RefSeq; XP_005260590.1; XM_005260533.2.
DR   PDB; 2JO8; NMR; -; A/B=432-480.
DR   PDB; 3COM; X-ray; 2.20 A; A/B=2-311.
DR   PDB; 4NR2; X-ray; 2.00 A; A/B/C/D/E/F/G/H=432-480.
DR   PDB; 4OH8; X-ray; 2.28 A; A=432-480.
DR   PDB; 5TWG; X-ray; 2.30 A; E=343-356.
DR   PDB; 5TWH; X-ray; 2.50 A; E=358-374.
DR   PDB; 6YAT; X-ray; 2.58 A; A/B=1-311.
DR   PDBsum; 2JO8; -.
DR   PDBsum; 3COM; -.
DR   PDBsum; 4NR2; -.
DR   PDBsum; 4OH8; -.
DR   PDBsum; 5TWG; -.
DR   PDBsum; 5TWH; -.
DR   PDBsum; 6YAT; -.
DR   AlphaFoldDB; Q13043; -.
DR   SMR; Q13043; -.
DR   BioGRID; 112665; 131.
DR   CORUM; Q13043; -.
DR   DIP; DIP-32491N; -.
DR   ELM; Q13043; -.
DR   IntAct; Q13043; 186.
DR   MINT; Q13043; -.
DR   STRING; 9606.ENSP00000361892; -.
DR   BindingDB; Q13043; -.
DR   ChEMBL; CHEMBL4598; -.
DR   DrugCentral; Q13043; -.
DR   GuidetoPHARMACOLOGY; 2225; -.
DR   iPTMnet; Q13043; -.
DR   MetOSite; Q13043; -.
DR   PhosphoSitePlus; Q13043; -.
DR   BioMuta; STK4; -.
DR   DMDM; 13124559; -.
DR   EPD; Q13043; -.
DR   jPOST; Q13043; -.
DR   MassIVE; Q13043; -.
DR   MaxQB; Q13043; -.
DR   PaxDb; Q13043; -.
DR   PeptideAtlas; Q13043; -.
DR   PRIDE; Q13043; -.
DR   ProteomicsDB; 59119; -. [Q13043-1]
DR   ProteomicsDB; 59120; -. [Q13043-2]
DR   Antibodypedia; 3325; 509 antibodies from 41 providers.
DR   DNASU; 6789; -.
DR   Ensembl; ENST00000372801.5; ENSP00000361887.1; ENSG00000101109.12. [Q13043-2]
DR   Ensembl; ENST00000372806.8; ENSP00000361892.3; ENSG00000101109.12. [Q13043-1]
DR   GeneID; 6789; -.
DR   KEGG; hsa:6789; -.
DR   MANE-Select; ENST00000372806.8; ENSP00000361892.3; NM_006282.5; NP_006273.1.
DR   UCSC; uc002xnb.4; human. [Q13043-1]
DR   CTD; 6789; -.
DR   DisGeNET; 6789; -.
DR   GeneCards; STK4; -.
DR   HGNC; HGNC:11408; STK4.
DR   HPA; ENSG00000101109; Tissue enhanced (bone).
DR   MalaCards; STK4; -.
DR   MIM; 604965; gene.
DR   MIM; 614868; phenotype.
DR   neXtProt; NX_Q13043; -.
DR   OpenTargets; ENSG00000101109; -.
DR   Orphanet; 314689; Combined immunodeficiency due to STK4 deficiency.
DR   PharmGKB; PA36215; -.
DR   VEuPathDB; HostDB:ENSG00000101109; -.
DR   eggNOG; KOG0574; Eukaryota.
DR   GeneTree; ENSGT00940000159787; -.
DR   InParanoid; Q13043; -.
DR   OMA; FLKSWSV; -.
DR   OrthoDB; 967913at2759; -.
DR   PhylomeDB; Q13043; -.
DR   TreeFam; TF354217; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q13043; -.
DR   Reactome; R-HSA-2028269; Signaling by Hippo.
DR   SignaLink; Q13043; -.
DR   SIGNOR; Q13043; -.
DR   BioGRID-ORCS; 6789; 11 hits in 1111 CRISPR screens.
DR   ChiTaRS; STK4; human.
DR   EvolutionaryTrace; Q13043; -.
DR   GeneWiki; STK4; -.
DR   GenomeRNAi; 6789; -.
DR   Pharos; Q13043; Tchem.
DR   PRO; PR:Q13043; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q13043; protein.
DR   Bgee; ENSG00000101109; Expressed in colonic epithelium and 188 other tissues.
DR   ExpressionAtlas; Q13043; baseline and differential.
DR   Genevisible; Q13043; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IGI:MGI.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; TAS:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0060706; P:cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IDA:MGI.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0003157; P:endocardium development; IEA:Ensembl.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0046621; P:negative regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0001841; P:neural tube formation; IEA:Ensembl.
DR   GO; GO:0035265; P:organ growth; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:1903945; P:positive regulation of hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:1904237; P:positive regulation of substrate-dependent cell migration, cell attachment to substrate; IEA:Ensembl.
DR   GO; GO:0060215; P:primitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:MGI.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0060800; P:regulation of cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 4.10.170.10; -; 1.
DR   IDEAL; IID00168; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024205; Mst1_SARAH_domain.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR011524; SARAH_dom.
DR   Pfam; PF11629; Mst1_SARAH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50951; SARAH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Coiled coil; Cytoplasm; Direct protein sequencing; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..487
FT                   /note="Serine/threonine-protein kinase 4"
FT                   /id="PRO_0000086691"
FT   CHAIN           1..326
FT                   /note="Serine/threonine-protein kinase 4 37kDa subunit"
FT                   /id="PRO_0000413735"
FT   CHAIN           327..487
FT                   /note="Serine/threonine-protein kinase 4 18kDa subunit"
FT                   /id="PRO_0000413736"
FT   DOMAIN          30..281
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          433..480
FT                   /note="SARAH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00310"
FT   REGION          303..332
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          290..310
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        149
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         36..44
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         59
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   SITE            326..327
FT                   /note="Cleavage; by caspase-3"
FT   SITE            349..350
FT                   /note="Cleavage; by caspase-3"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   MOD_RES         3
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         183
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15109305"
FT   MOD_RES         265
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         320
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         340
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         367
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         387
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:17726016,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         410
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         433
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JI11"
FT   VAR_SEQ         436..462
FT                   /note="LKSWTVEDLQKRLLALDPMMEQEIEEI -> KTSQEQQSGKDICIQNCQGNL
FT                   LCRYAF (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_019851"
FT   VAR_SEQ         463..487
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_019852"
FT   VARIANT         162
FT                   /note="H -> N (in dbSNP:rs55850759)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041123"
FT   VARIANT         310
FT                   /note="R -> Q (in dbSNP:rs35447878)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041124"
FT   VARIANT         312
FT                   /note="V -> M (in dbSNP:rs17420378)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:7665586"
FT                   /id="VAR_027040"
FT   VARIANT         355
FT                   /note="I -> T (in dbSNP:rs35944046)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041125"
FT   VARIANT         416
FT                   /note="P -> L (in dbSNP:rs33963346)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041126"
FT   MUTAGEN         59
FT                   /note="K->R: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:15109305,
FT                   ECO:0000269|PubMed:16930133"
FT   MUTAGEN         175
FT                   /note="T->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15109305"
FT   MUTAGEN         177
FT                   /note="T->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15109305"
FT   MUTAGEN         183
FT                   /note="T->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:15109305"
FT   MUTAGEN         326
FT                   /note="D->N: Resistant to proteolytic cleavage by caspase
FT                   during apoptosis; when associated with N-349."
FT                   /evidence="ECO:0000269|PubMed:11278283"
FT   MUTAGEN         349
FT                   /note="D->N: Resistant to proteolytic cleavage by caspase
FT                   during apoptosis; when associated with N-326."
FT                   /evidence="ECO:0000269|PubMed:11278283"
FT   MUTAGEN         444
FT                   /note="L->P: Loss of homodimerization, activation, and
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:15109305"
FT   CONFLICT        222
FT                   /note="P -> R (in Ref. 1; AAA83254)"
FT                   /evidence="ECO:0000305"
FT   HELIX           19..22
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           26..29
FT                   /evidence="ECO:0007829|PDB:6YAT"
FT   STRAND          30..35
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          43..49
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   TURN            50..52
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          55..62
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           68..78
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          88..94
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          97..103
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           110..117
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           123..142
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           152..154
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          155..157
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          163..165
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           193..196
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   STRAND          197..199
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           205..219
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   TURN            223..226
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           229..238
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           247..249
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           252..261
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   TURN            266..268
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           272..275
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           279..282
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           287..290
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           291..297
FT                   /evidence="ECO:0007829|PDB:3COM"
FT   HELIX           433..436
FT                   /evidence="ECO:0007829|PDB:4NR2"
FT   HELIX           441..478
FT                   /evidence="ECO:0007829|PDB:4NR2"
SQ   SEQUENCE   487 AA;  55630 MW;  150758EBC5F77D5C CRC64;
     METVQLRNPP RRQLKKLDED SLTKQPEEVF DVLEKLGEGS YGSVYKAIHK ETGQIVAIKQ
     VPVESDLQEI IKEISIMQQC DSPHVVKYYG SYFKNTDLWI VMEYCGAGSV SDIIRLRNKT
     LTEDEIATIL QSTLKGLEYL HFMRKIHRDI KAGNILLNTE GHAKLADFGV AGQLTDTMAK
     RNTVIGTPFW MAPEVIQEIG YNCVADIWSL GITAIEMAEG KPPYADIHPM RAIFMIPTNP
     PPTFRKPELW SDNFTDFVKQ CLVKSPEQRA TATQLLQHPF VRSAKGVSIL RDLINEAMDV
     KLKRQESQQR EVDQDDEENS EEDEMDSGTM VRAVGDEMGT VRVASTMTDG ANTMIEHDDT
     LPSQLGTMVI NAEDEEEEGT MKRRDETMQP AKPSFLEYFE QKEKENQINS FGKSVPGPLK
     NSSDWKIPQD GDYEFLKSWT VEDLQKRLLA LDPMMEQEIE EIRQKYQSKR QPILDAIEAK
     KRRQQNF
//
